【摘要】 目的　探讨冠心病患者循环活化血小板 (CAP)的变化及对阿斯匹林抵抗的处理。方法　以纤维蛋白原受体 (PAC - 1)、P -选择素 (CD6 2P)作为分子标志物 ,FCM三色免疫荧光分析CAP ,观察正常人及冠心病患者CAP变化。结果　正常人静止血小板膜表面PAC - 1和CD6 2P表达较低。冠心病患者血液中表达PAC - 1的数量与正常人比较有非常显著差异 (P <0 0 0 1)。阿斯匹林治疗后冠心病患者的PAC - 1及CD6 2P表达呈下降趋势 (P值分别为 <0 0 0 1及 <0 0 5)。抵克力特可显著降低存在阿斯匹林抵抗现象的病人PAC - 1的表达 (P <0 0 0 1)。结论　冠心病患者血液中PAC- 1明显增高 ,阿斯匹林可以显著降低冠心病患者PAC - 1及CD6 2P的表达水平。抵克力特可显著降低存在阿斯匹林抵抗现象的病人PAC - 1的表达更多还原

【Abstract】 Objective To explore the clinical signi fi cance of CAP changes and the management of aspirin resistance in CHD patients.Methods Study included 103 CHD patients and 35 healthy pe ople.PAC-1 and CD62P as the molecular markers of CAP were analyzed by FCM 3-colo r immunofluorescence.PAC-1 and CD62P were measured in all study objects.Results The quantity of PAC-1 in 103 CHD patients is significan tly higher than that in normal people( P <0 001).The expression of PAC-1 and CD62P of CAP decreased significantly( P <0 001 and P <0 05,respectivel y) after aspirin treatment in CHD patients.Ticlopidine can dramatically reduce t he expression of PAC-1 in CHD patients with aspirin resistance ( P <0 001). Conclusions The expression of PAC-1 and CD62P in CHD pa tients obviously increased.Aspirin can significantly dicrease the level of PAC-1 and CD62P in CHD patients.Ticlopidine can dramatically reduce the expression of PAC-1 in CHDpatients with aspirin resistance.更多还原